MGC Diagnostics Unveils Meridian Series™: The Future of Cardiorespiratory Diagnostic Testing

ST. PAUL, MN - November 10, 2025 - MGC Diagnostics, a leading provider of cardiorespiratory diagnostic solutions, today announced the launch of its groundbreaking Meridian Series™ cardiorespiratory diagnostic systems. This innovative new product line is engineered to deliver unparalleled performance in assessing cardiovascular and respiratory function, ensuring the highest level of performance.

The Meridian Series™ represents a significant leap forward in cardiorespiratory diagnostics, offering a comprehensive suite of capabilities from routine spirometry to advanced cardiopulmonary exercise testing (CPET). The modular system redefines diagnostic standards with a focus on accuracy and precision to provide clinicians with the precise information needed for confident diagnosis and effective patient management. Its intuitive interface and robust analytical tools streamline workflows, allowing healthcare professionals to dedicate more time to patient care.

"The Meridian Series™ is a direct response to the evolving needs of cardiorespiratory diagnostics. We focused on delivering a system that offers unparalleled precision in everything from spirometry to CPET, while also integrating seamlessly into clinical workflows. This advanced technology is designed to simplify complex testing, eliminate laboratory downtime, and be cost-effective. All of which ultimately enhances the quality of patient care," said Dr. Zack Roloff, Gas Exchange Product Manager at MGC Diagnostics.

Raul Carreras, President of MGC Diagnostics, added, "What makes the Meridian special is its modular design with its versatile cart and tabletop setups. Coupled with the most powerful software on the market, Ascent™, you get a system that's not just another piece of equipment - it's a complete solution designed to make a real difference in how healthcare providers work and, most importantly, in the lives of the patients they serve."

The Meridian Series™ is poised to transform the landscape of cardiorespiratory diagnostics, offering a scalable and adaptable solution for a wide range of clinical settings, from small practices to large hospitals and educational/research institutions. Its modular design ensures future compatibility and upgradeability, protecting investment and adapting to evolving clinical needs.

About MGC Diagnostics

MGC Diagnostics Corporation is a global medical technology company dedicated to cardiorespiratory health solutions. The company, with facilities in Belgium, Germany, France, and Australia, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and, in the United States, France, Belgium and Australia, primarily through a direct sales force targeting heart and lung specialists located in hospitals, university based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). On December 28, 2022, MGC Diagnostics was acquired by CAIRE Inc., a leading global manufacturer of oxygen therapy and on-site generation systems.

For more information, please contact MGC Diagnostics Corporation at 800.950.5597 or visit mgcdiagnostics.com.